M&A / Deals Isomorphic Labs receives $2.1bn for AI drug development Pharmaceutical TechnologyIsomorphic Labs has secured $2.1bn in funding to expedite its transition from developing AI models to deploying them on a larger scale.Read full story pharminent May 13, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Isomorphic Labs has secured $2.1bn in funding to expedite its transition from developing AI models to deploying them on a larger scale. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Makary resigns, with Diamantas named as acting FDA commissionerNext: Novo, Lilly trade oral GLP-1 data readouts at ECO Related Stories M&A / Deals Spero snaps up Innovent immunology drug in strategic pivot pharminent July 14, 2026 M&A / Deals AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B pharminent July 14, 2026 M&A / Deals Novartis and Chai Discovery collaborate on antibody identification pharminent July 14, 2026
